Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

Tom Nolan reviews this week’s research Cannabinol—aka CBD—is a modern day tonic for almost any ailment, available in all good vape shops and petrol stations. In 2023, the Food Standards Agency cut the ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

Can it really be maintained after they’re discontinued on top-selling drugs such as Ozempic or Wegovy, or is rebound weight gain simply a natural part of the process? For many adult patients taking ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...